N. Engl. J. Med.
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Abstract
Background
Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer have poor prognoses. The benefit of adjuvant chemotherapy in these patients remains unclear.
Methods
We randomly assigned 910 patients with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (containing anthracycline, taxane, or both) to receive standard postsurgical treatment either with capecitabine or without (control). The primary end point was disease-free survival. Secondary end points included overall survival.
Results
The result of the prespecified interim analysis met the primary end point, so this trial was terminated early. The final analysis showed that disease-free survival was longer in the capecitabine group than in the control group (74.1% vs. 67.6% of the patients were alive and free from recurrence or second cancer at 5 years; hazard ratio for recurrence, second cancer, or death, 0.70; 95% confidence interval [CI], 0.53 to 0.92; P=0.01). Overall survival was longer in the capecitabine group than in the control group (89.2% vs. 83.6% of the patients were alive at 5 years; hazard ratio for death, 0.59; 95% CI, 0.39 to 0.90; P=0.01). Among patients with triple-negative disease, the rate of disease-free survival was 69.8% in the capecitabine group versus 56.1% in the control group (hazard ratio for recurrence, second cancer, or death, 0.58; 95% CI, 0.39 to 0.87), and the overall survival rate was 78.8% versus 70.3% (hazard ratio for death, 0.52; 95% CI, 0.30 to 0.90). The hand-foot syndrome, the most common adverse reaction to capecitabine, occurred in 73.4% of the patients in the capecitabine group.
Conclusions
After standard neoadjuvant chemotherapy containing anthracycline, taxane, or both, the addition of adjuvant capecitabine therapy was safe and effective in prolonging disease-free survival and overall survival among patients with HER2-negative breast cancer who had residual invasive disease on pathological testing. (Funded by the Advanced Clinical Research Organization and the Japan Breast Cancer Research Group; CREATE-X UMIN Clinical Trials Registry number, UMIN000000843 .).
Related Questions
Would you consider adjuvant capecitabine for a patient with triple-negative metaplastic carcinoma who has microinvasive residual disease (ypT1miN0) following neoadjuvant therapy?
For a patient with triple-negative metaplastic breast cancer and microinvasive residual disease (ypT1miN0)following neoadjuvant therapy, the decision to use adjuvant capecitabine is nuanced and not definitively addressed in current guidelines or trials. General TNBC with Residual Disease: Multiple...
Given the final publication of NSABP B-51, for which patients meeting trial eligibility would you still recommend regional nodal irradiation?
The very first thing that should occur before one makes a decision about what they are going to do is to understand how the trial was designed and who was actually accrued to it. The first point is that B51 was a superiority and not a non-inferiority trial. A very related point to that is that they ...
Would you offer adjuvant AC + pembrolizumab for a triple negative breast cancer patient whose tumor progressed on carboplatin + paclitaxel + pembrolizumab on KEYNOTE-522 and required urgent surgery (ypT3 ypN0)?
In these situations, adjuvant AC should be considered. Anthracyclines have been shown to improve outcomes in high-risk TNBC in the adjuvant setting across multiple trials. CREATE-X used adjuvant capecitabine in patients who had residual disease after neoadjuvant anthracyclines and taxanes. It wasn't...
How do you treat a patient with TNBC, BRCA WT, who received KEYNOTE-522 with residual disease post neoadjuvant therapy?
Yes, in this (unfortunately high-high-risk) situation, I would continue adjuvant pembrolizumab as per the KEYNOTE-522 trial, and add adjuvant capecitabine per the CREATE-X trial. Though these two agents were not specifically studied together in this exact setting, there is other safety data to reass...
Do you consider post-NAC isolated tumor cells in LNs to be residual disease in TNBC to justify capecitabine?
The brief answer is yes, I would. These patients were included in the CREATE-X trial (Masuda et al., PMID 28564564). Also, there is data out of Boston that following neoadjuvant chemotherapy, patients with even isolated tumor cells in lymph nodes have a poorer prognosis (Wong et al., PMID 31228134)....
Is there a role for adjuvant pembrolizumab/capecitabine in a patient with TNBC who receives neoadjuvant AC-T with residual disease found at time of surgery?
Based on CREATE-X, there would be data to support using adjuvant capecitabine in this scenario. As for pembrolizumab, there is emerging data that the benefit of the checkpoint inhibitor may be limited to the neoadjuvant setting based on the recent negative IMpassion030 trial of adjuvant atezolizumab...
What neoadjuvant regimen would you consider using for a healthy patient with node positive TNBC who is refusing anthracycline?
In a patient with node-positive TNBC not eligible for an anthracycline, or refusing an anthracycline, I would strongly consider proceeding with a platinum + taxane + pembrolizumab, mirroring the NeoPACT trial presented by @Dr. First Last at ASCO 2022, which is the same regimen of carboplatin/docetax...
Would you consider avoidance of AC and proceeding to surgery in a cT2N0 TNBC patient who achieves a significant clinical response to carboplatin, paclitaxel, and pembrolizumab as part of the KEYNOTE-522 regimen?
Full disclosure -- I trained in breast cancer at UCLA, where we generally avoid anthracyclines. The main downside of adding an anthracycline to a taxane-based regimen is the elevated risk of leukemia, myelodysplasia, and congestive heart failure or weakening of the heart long-term. I use neoadjuvant...
Is there a role for adjuvant capecitabine in sequence with abemaciclib for high risk HR+ breast cancer with residual disease?
Several randomized trials and meta-analyses have failed to show the benefit of adding capecitabine in Neo-adjuvant or adjuvant setting, except for selected TNBC patients. GEICAM/2003-10 and FinXX are few of those well-conducted studies that explored the addition of capecitabine in early stage breast...
How would you treat an elderly female with residual TNBC following surgery and neoadjuvant Carboplatin and Paclitaxel?
I think there will be some differing opinions on this. There are a number of things I would factor in assuming the patient has enough life expectancy where the breast cancer is the main mortality risk. 1) Data from carbo/taxane neoadjuvant trials (Sharma et al CCR 2018) and others suggest RCB1 patie...
Would you consider adding pembrolizumab to adjuvant chemotherapy in a patient with stage 3 TNBC who did not receive neoadjuvant treatment?
It seems that we might be missing some key clinical information here. However, I assume that this was high risk enough - given the ki-67, potentially LN positive, and larger size tumor to make the treating physician concerned. As a first point, while the ctDNA reflects (based on accumulating data) p...
How do you sequence capecitabine and olaparib, if at all, in patients with BRCA+ TNBC and residual disease after neoadjuvant chemotherapy?
Patients with germline PV in BRCA 1/2 and residual disease following NAC in early TNBC have two options that likely represent standard of care in the adjuvant setting, a) adjuvant capecitabine (CREATE-X, EA1131) and/or b) adjuvant olaparib (NSABP B55). B55 did not allow for any further adjuvant chem...
How do you approach adjuvant therapy for a premenopausal patient with a pathologic BRCA1 mutation whose TNBC had a complete response to neoadjuvant chemotherapy except for an ITC in one LN?
This is technically a Stage 0/RCB-I after neoadjuvant chemo when I calculated it. This patient would not qualify for the current clinical trials looking at additional therapy (ECOG capecitabine vs platinum, now closed; the SWOG pembrolizumab vs observation, still accruing). Looking at CREATE-X, the ...
How do you manage hand-foot syndrome associated with capecitabine (and other conventional chemotherapy agents)?
In the breast cancer world, I see hand-foot syndrome most commonly with capecitabine. I have used topical 10% urea cream with a reasonable amount of success. I have noticed that using it prophylactically seems to help with the prevention of hand-foot syndrome to quite an extent. A couple of randomiz...
What chemotherapy would you offer (if any) in a young patient after resection and radiation of a single site of metastatic PDL1 positive, triple negative breast cancer?
This is a challenging situation, as the patient is clearly at very high risk of developing other sites of metastatic disease but there is little data on the benefit of chemotherapy or immunotherapy in reducing that risk, delaying the development of metastatic disease, or improving survival. If the p...
Would you consider adjuvant capecitabine in a premenopausal patient with HR-positive inflammatory breast cancer who had residual disease after neoadjuvant chemotherapy?
Yes, I would consider adjuvant capecitabine for a patient with residual invasive disease after standard neoadjuvant chemotherapy (NAC) for HR+ inflammatory breast cancer. Given the uncertainties about the absolute benefit in recurrence and mortality in this specific situation, I would discuss this w...
Will you offer capecitabine for 1 year to all localized TNBC patients?
The SYSUCC trial enrolled stage Ib-III TNBC patients who had either neoadjuvant or adjuvant systemic treatment followed by standard local therapy, and randomized the patients to either get 1 year of metronomic dosed capecitabine (650mg/m2 BID no break) x 12 months or observation. They observed an im...
How would you approach a patient with a locoregional recurrence TNBC who requires neoadjuvant treatment?
My assumption is that the patient developed this currently unresectable LRR after completing neoadjuvant chemotherapy and surgery, and has to be considered at high risk for both local complications, which is why you want to administer 'neoadjuvant' therapy (although I'm not sure that the term is app...
What pathologic response criteria do you use to determine the need for further adjuvant therapy in patients with breast cancer?
The question about which response criteria might guide further adjuvant therapy in HR+ disease after neo-adjuvant chemo is of unclear clinical significance currently. Until CDK4/6 inhibitors receive an FDA indication in the adjuvant setting, the only "systemic therapy" decision to be made after neo-...
How might you alter treatment for a breast cancer patient receiving standard taxane-based adjuvant therapy who develops an adverse reaction to the taxane (e.g. severe pneumonitis) after completion of ddAC?
The two questions to address in making a decision are how sure we are that the paclitaxel is responsible for the pneumonitis and how much we expect the taxane to contribute to reducing the patient's risk of recurrence.In regards the former, we know that many hypersensitivity reactions to standard (s...